194 related articles for article (PubMed ID: 7528458)
1. [Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
Larosa M; Ferretti S; Salsi P; Simonazzi M
Acta Biomed Ateneo Parmense; 1994; 65(1-2):23-8. PubMed ID: 7528458
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Kuritzky L; Rosenberg MT; Sadovsky R
Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience: symptomatic management of BPH with terazosin.
Dunzendorfer U
Urology; 1988 Dec; 32(6 Suppl):27-31. PubMed ID: 2462302
[TBL] [Abstract][Full Text] [Related]
4. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
5. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Fourcade RO
Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
7. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
8. Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
Mudiyala R; Ahmed A
J Am Geriatr Soc; 2003 Mar; 51(3):424-6. PubMed ID: 12588590
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
[TBL] [Abstract][Full Text] [Related]
10. [Terazosin in the treatment of benign prostatic hypertrophy].
Andres M; De Cobelli O; Carmignani L; Musci R; Kocjancic E; Panizzutti M; Rocco F
Arch Ital Urol Androl; 1995 Feb; 67(1):37-9. PubMed ID: 7538386
[TBL] [Abstract][Full Text] [Related]
11. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
Dunzendorfer U
Arzneimittelforschung; 1989 Oct; 39(10):1289-91. PubMed ID: 2482025
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
13. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
[TBL] [Abstract][Full Text] [Related]
15. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.
Lepor H
Prostate Suppl; 1990; 3():75-84. PubMed ID: 1689172
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
17. [A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
Park YC; Nishioka T; Arai Y; Tomoyoshi T; Kurita T; Hayashida H; Nagai N; Inoue H; Kataoka K; Kitagawa Y
Hinyokika Kiyo; 1992 Jul; 38(7):857-68. PubMed ID: 1381869
[TBL] [Abstract][Full Text] [Related]
18. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
Plosker GL; Goa KL
Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of terazosin in patients with benign prostatic hyperplasia.
Matzkin H; Soloway MS; Rangel MC; Laddu A
Eur Urol; 1992; 21(2):126-30. PubMed ID: 1379921
[TBL] [Abstract][Full Text] [Related]
20. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
